



Proteomics International

LABORATORIES LTD

30 August 2021

The Manager
Market Announcements Office
Australian Securities Exchange

Dear Manager,

ANNUAL RESULTS

In accordance with the ASX Listing Rules, attached is the Appendix 4E – Preliminary Final Report.

The Annual Report to shareholders will be released separately.

The Company also advises that the 2021 Annual General Meeting will be held on 25 November 2021. The deadline to receive director nominations is 1 October 2021.

This announcement was authorised to be given to ASX by the Board of Directors of Proteomics International Laboratories Ltd.

Yours faithfully,

Karen Logan
Company Secretary

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Appendix 4E

Preliminary Final Report
Proteomics International Laboratories Ltd
ABN 78 169 979 971

Dates

Financial Year Ended	30 June 2021
Previous Corresponding Reporting Period	Financial year ended 30 June 2020

Results for Announcement to the Market

	Current Period (30 Jun 2021) \$	Percentage increase /(decrease) over previous corresponding period	Previous Corresponding Period (30 Jun 2020) \$
Revenue from ordinary activities ¹	1,451,040	(9%)	1,590,031
(Loss) from ordinary activities after tax attributable to members ²	(2,859,663)	64%	(1,743,770)
(Loss) for the period attributable to members	(2,859,663)	64%	(1,743,770)

Notes:

1. Revenue from continuing operations, research grants and other income have been disclosed as revenue from ordinary activities.
2. Net loss for the period from continuing operations has been disclosed as loss from ordinary activities after tax attributable to members

Dividends (distributions)	Amount per security	Franked amount per security
Final Dividend	Nil	Nil
Interim Dividend	Nil	Nil
Record date for determining entitlements to the dividends (if any)	Not Applicable	

Commentary on the results for the financial year ended 30 June 2021

Brief explanation of any of the figures reported above necessary to enable the figures to be understood:

Medical technology company Proteomics International Laboratories Ltd (ASX:PIQ; Proteomics International or the Company) presents this financial report for the year ended 30 June 2021, with the following explanation of the results:

- Operating revenue from analytical services remained robust despite economic uncertainties at \$1.31m, an 8% decrease compared to the previous year.
- Combined income from all sources declined 1% to \$2.99 million. Revenue from ordinary activities encapsulates income from analytical services, State and Federal COVID-19 stimulus packages, and grant income including the R&D Tax Incentive.
- Operational expenditure increased to \$5.8 million, and focused on the commercialisation of PromarkerD, upgrading of laboratory instruments, and expansion of the diagnostics pipeline.
- The loss from ordinary activities increased 64% to \$2.86 million, which reflects normal operational costs and non-cash items.
- The net cash outflow from operating activities was \$2.21 million.
- At 30 June 2021 the Company had cash reserves of \$5.6 million, and trade and other receivables of \$0.3 million. On the back of the Company's research and development focus it anticipates an R&D Tax Incentive cash rebate of \$1.29 million, to be received in the December quarter 2021.

A full description of Proteomics International's operational activities is contained in the Company's Annual Report for 2021 available here:

www.proteomics.com.au/investors/reports-main-page/2021-annual-financial-reports/

ANNUAL GENERAL MEETING

In accordance with ASX Listing Rules 3.13.1 and 14.3, Proteomics International advises that its 2021 annual general meeting (AGM) is scheduled to be held on 25 November 2021. The Company encourages shareholders to attend the AGM and receive an update on the strategy and initiatives of the Group.

Net tangible assets per ordinary share

	30 June 2021	30 June 2020
	\$	\$
Net tangible asset per share	0.07	0.05

Details of Associates and Joint Venture Entities

Name of entity	Ownership Interest		Contribution to net profit/(loss)	
	2021 %	2020 %	2021 \$A	2020 \$A
	N/A	N/A	N/A	N/A
Associates				
Joint Venture Entities				
Aggregate Share of Losses				

Details of entities over which control has been gained or lost during the period

Name of entity	N/A
Date of gaining control	N/A
Commentary and contribution	N/A

Audit Status

This report is based on accounts to which one of the following applies: (Tick one)			
The accounts have been audited	<input checked="" type="checkbox"/>	The accounts have been subject to review	<input type="checkbox"/>
The accounts are in the process of being audited or subject to review	<input type="checkbox"/>	The accounts have not yet been audited or reviewed	<input type="checkbox"/>

If the accounts have not yet been audited and are likely to contain an independent audit report that is subject to a modified opinion, emphasis of matter or other matter paragraph, a description of the modified opinion, emphasis of matter or other matter:

Not applicable.

If the accounts have been audited contain an independent audit report that is subject to a modified opinion, emphasis of matter or other matter paragraph, a description of the modified opinion, emphasis of matter or other matter:

Not applicable.